Lead Product(s) : Resiniferatoxin
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RTX (resiniferatoxin) is a small molecule which is act as TRPV1 agonist, which is investigated for the treatment of knee pain in moderate to severe osteoarthritis of the knee (OAK) patients.
Product Name : MTX-071
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2023
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Grünenthal Starts Phase III Trials for Resiniferatoxin in Osteoarthritis-Related Pain
Details : RTX is an intra-articular injection of resiniferatoxin developed for the treatment of pain in patients with moderate to severe pain associated with knee osteoarthritis.
Product Name : RTX
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 18, 2022
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Shionogi
Deal Size : $670.0 million
Deal Type : Licensing Agreement
Details : The agreement includes competitive investment commitments for launch and commercialisation. Manufacturing and supply of RTX (resiniferatoxin) to Shionogi will be carried out exclusively by Grünenthal.
Product Name : RTX
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 08, 2022
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Shionogi
Deal Size : $670.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Grunenthal
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Mestex AG is a Swiss biotech company that has developed the innovative investigational medicine MTX-071 (resiniferatoxin) for the intra-articular treatment of pain associated with osteoarthritis of the knee.
Product Name : MTX-071
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 04, 2021
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Grunenthal
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 1 was an ascending dose safety study in 17 patients to assess the safety and preliminary efficacy of epidural administration of resiniferatoxin for the treatment of intractable pain due to cancer.
Product Name : MTX-071
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2021
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company begins enrollment in the phase 2 trial because data from the phase 1B of RTX (Resiniferatoxin) showed significant pain relief observed in patients with advanced OA disease and sustained pain relief last beyond 6 months.
Product Name : MTX-071
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 12, 2021
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The RTX clinical development program continues, with Phase 2 and 3 clinical trials planned in larger patient populations. The first Phase 2 trial will focus on identifying the recommended Phase 3 dose.
Product Name : MTX-071
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 07, 2021
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 1b trial was a placebo controlled ascending dose study with an open-label extension to assess the safety and preliminary efficacy of intra-articular administration of RTX or saline control for moderate to severe pain due to osteoarthritis of th...
Product Name : MTX-071
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2020
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This multicenter, open-label study enrolled 17 adults with intractable moderate to severe cancer pain. Subjects were treated with a one-time epidural administration of RTX at escalating dose level cohorts, ranging from 0.4 µg to 25 µg in 3 ml saline, i...
Product Name : MTX-071
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 22, 2020
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Safety in the higher dose cohort is expected to be supportive for testing RTX epidural administration in other advanced non-cancer disease related unmet clinical needs.
Product Name : MTX-071
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 27, 2020
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable